Immunotherapies

The introduction of immune checkpoint inhibitors as a treatment for NSCLC has been viewed as a major advancement. The expert faculty will provide their perspectives on neoadjuvant, perioperative, and adjuvant treatment of early-stage NSCLC and new data on the first-line treatment of advanced NSCLC with immunotherapy, as well as how these new data can be applied to clinical practice.

Available CME Activities

Informed Choices in NSCLC: Optimal Use of Immunotherapies Across All Stages of Disease

Archived Activities

Exploring the Latest Data for the ICI-Based Treatment of All Stages of NSCLC: Interactive Infographic

Insights Into Neoadjuvant and Perioperative Treatment of Early-Stage NSCLC: Expert Discussion 1

Insights Into the Adjuvant Treatment of Early-Stage NSCLC: Expert Discussion 2

Insights Into the First-Line Treatment of Advanced NSCLC With ICI-Based Regimens: Expert Discussion 3

The Latest Data and Insights on ICI-Based Regimens from Early Stages to Advanced Disease

The HOPE for NSCLC Learning Center is an educational resource developed by Paradigm Medical Communications in collaboration with The American Lung Association. The Learning Center, which features multiple individually accredited CME activities and patient and clinician resources, is for educational purposes only. Healthcare professionals are expected to employ their own knowledge and judgement during any discussion with, or treatment of, their patients.

For questions or technical support please email us at contactus@paradigmmc.com.